About Abbott Laboratories (NYSE:ABT)
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Pharmaceuticals
- Sub-Industry: Health Care Equipment
- Symbol: NYSE:ABT
- CUSIP: 00282410
- Web: www.abbott.com
- Market Cap: $97.44 billion
- Outstanding Shares: 1,737,443,000
- 50 Day Moving Avg: $53.41
- 200 Day Moving Avg: $48.67
- 52 Week Range: $37.38 - $56.69
Sales & Book Value:
- Trailing P/E Ratio: 78.54
- Foreward P/E Ratio: 19.89
- P/E Growth: 1.96
- Annual Revenue: $23.61 billion
- Price / Sales: 4.13
- Book Value: $18.19 per share
- Price / Book: 3.08
- Annual Dividend: $1.06
- Dividend Yield: 1.9%
- EBITDA: $5.14 billion
- Net Margins: 8.21%
- Debt-to-Equity Ratio: 0.75%
- Current Ratio: 2.94%
- Quick Ratio: 2.41%
- Average Volume: 5.48 million shs.
- Beta: 1.06
- Short Ratio: 2.35
Frequently Asked Questions for Abbott Laboratories (NYSE:ABT)
What is Abbott Laboratories' stock symbol?
Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."
How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?
Abbott Laboratories declared a quarterly dividend on Friday, September 15th. Investors of record on Friday, October 13th will be paid a dividend of $0.265 per share on Wednesday, November 15th. This represents a $1.06 dividend on an annualized basis and a yield of 1.89%. The ex-dividend date is Thursday, October 12th. View Abbott Laboratories' Dividend History.
How were Abbott Laboratories' earnings last quarter?
Abbott Laboratories (NYSE:ABT) posted its earnings results on Wednesday, October, 18th. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.65 by $0.01. The firm earned $6.83 billion during the quarter, compared to the consensus estimate of $6.72 billion. The company's quarterly revenue was up 28.8% compared to the same quarter last year. During the same period last year, the company earned $0.59 EPS. View Abbott Laboratories' Earnings History.
When will Abbott Laboratories make its next earnings announcement?
What guidance has Abbott Laboratories issued on next quarter's earnings?
Abbott Laboratories updated its fourth quarter earnings guidance on Wednesday, October, 18th. The company provided earnings per share guidance of $0.72-0.74 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.73.
Where is Abbott Laboratories' stock going? Where will Abbott Laboratories' stock price be in 2017?
14 equities research analysts have issued 12 month price objectives for Abbott Laboratories' shares. Their forecasts range from $42.00 to $68.00. On average, they anticipate Abbott Laboratories' stock price to reach $57.64 in the next year. View Analyst Ratings for Abbott Laboratories.
What are analysts saying about Abbott Laboratories stock?
Here are some recent quotes from research analysts about Abbott Laboratories stock:
- 1. According to Zacks Investment Research, "Over the past three months, Abbott has been trading above the broader industry. While we await Abbott's third-quarter 2017 earnings result, the promising full year guidance is indicative of brighter prospects ahead. In fact, the strong guidance is backed by the company’s expectations to gain more synergies from the St. Jude merger. Overall, we look forward to Abbott’s plans to expand in core therapeutic areas. Recently, the company's FreeStyle Libre Flash received the FDA approval. Also, the company has received FDA approval for magnetic resonance-conditional labeling for its Ellipse implantable cardioverter defibrillator recently. On the flip side, Abbott’s sluggish pediatric business in China continues to dent growth. Management is also concerned about the economic problems in Venezuela that are expected to remain unresolved for some time. Meanwhile, we still wait for the Alere integration details." (10/16/2017)
- 2. Jefferies Group LLC analysts commented, "Investment summary: We are reiterating our Overweight rating for CORI and we are raising our PT by $2 to $12 following the positive donepezil patch bioequivalence results. Progress in the development of a proprietary pipeline is key, in our opinion, to the performance of the shares. Successful development of patch formulations of donepezil (Aricept) and/or memantine (Namenda) should position the company well to more-effectively monetize the transdermal drug delivery platform, in our opinion. Retention of meaningful commercialization rights could enable the company to turn the corner and pursue other opportunities more broadly, in our opinion. Corplex donepezil pilot study shows bioequivalence. Management reported that the Corplex donepezil pilot study met the FDA statistical criteria for bioequivalence. We note, too, that the patch was well-tolerated, with good skin and GI tolerability." (5/12/2017)
Who are some of Abbott Laboratories' key competitors?
Some companies that are related to Abbott Laboratories include Merck & Company (MRK), Amgen (AMGN), Sanofi (SNY), Novo Nordisk A/S (NVO), Bristol-Myers Squibb Co (BMY), GlaxoSmithKline PLC (GSK), Celgene Corporation (CELG), Eli Lilly and Company (LLY), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Catalent (CTLT), Patheon NV (PTHN) and Taro Pharmaceutical Industries (TARO).
Who are Abbott Laboratories' key executives?
Abbott Laboratories' management team includes the folowing people:
- Miles D. White, Chairman of the Board, Chief Executive Officer
- Brian B. Yoor, Chief Financial Officer, Senior Vice President - Finance
- Michael T. Rousseau, President - Cardiovascular and Neuromodulation
- Hubert L. Allen, Executive Vice President, General Counsel, Secretary
- Stephen R. Fussell, Executive Vice President - Human Resources
- Brian J. Blaser, Executive Vice President - Diagnostics Products
- John M. Capek Ph.D., Executive Vice President - Ventures
- Robert B. Ford, Executive Vice President - Medical Devices
- Heather L. Mason, Executive Vice President - Nutritional Products
- Roger M Bird, Senior Vice President - U.S. Nutrition
Who owns Abbott Laboratories stock?
Abbott Laboratories' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Diamond Hill Capital Management Inc. (0.64%), Independent Franchise Partners LLP (0.58%), Rockefeller Financial Services Inc. (0.13%), Nationwide Fund Advisors (0.10%), Hermes Investment Management Ltd. (0.07%) and APG Asset Management N.V. (0.06%). Company insiders that own Abbott Laboratories stock include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.
Who sold Abbott Laboratories stock? Who is selling Abbott Laboratories stock?
Abbott Laboratories' stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Diamond Hill Capital Management Inc., Rockefeller Financial Services Inc., Nationwide Fund Advisors, State Treasurer State of Michigan, PGGM Investments, Oakbrook Investments LLC and Bridges Investment Counsel Inc.. Company insiders that have sold Abbott Laboratories stock in the last year include Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Robert E Funck, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.
Who bought Abbott Laboratories stock? Who is buying Abbott Laboratories stock?
Abbott Laboratories' stock was bought by a variety of institutional investors in the last quarter, including Independent Franchise Partners LLP, Locust Wood Capital Advisers LLC, Hermes Investment Management Ltd., Sit Investment Associates Inc., Assenagon Asset Management S.A., Tompkins Financial Corp, Curbstone Financial Management Corp and Moloney Securities Asset Management LLC. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.
How do I buy Abbott Laboratories stock?
Shares of Abbott Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abbott Laboratories' stock price today?
MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Abbott Laboratories stock can currently be purchased for approximately $56.08.
Consensus Ratings for Abbott Laboratories (NYSE:ABT) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||5 Hold Ratings, 9 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.64)|
|Consensus Price Target: ||$57.64 (2.79% upside)|Consensus Price Target History for Abbott Laboratories (NYSE:ABT)
Analysts' Ratings History for Abbott Laboratories (NYSE:ABT)
(Data available from 10/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/19/2017||Barclays PLC||Reiterated Rating||Overweight||N/A|
|10/19/2017||Citigroup Inc.||Reiterated Rating||Neutral||N/A|
|10/19/2017||BMO Capital Markets||Reiterated Rating||Market Perform||N/A|
|10/19/2017||Cowen and Company||Set Price Target||Buy||$55.00 -> $68.00||N/A|
|10/19/2017||Stifel Nicolaus||Boost Price Target||Buy -> Buy||$58.00 -> $63.00||N/A|
|10/19/2017||Royal Bank Of Canada||Boost Price Target||Outperform -> Outperform||$55.00 -> $60.00||N/A|
|10/19/2017||Jefferies Group LLC||Reiterated Rating||Buy||$65.00||N/A|
|10/6/2017||J P Morgan Chase & Co||Initiated Coverage||Neutral -> Neutral||$60.00||N/A|
|10/4/2017||Bank of America Corporation||Reiterated Rating||Buy||$56.00 -> $60.00||N/A|
|9/28/2017||Wells Fargo & Company||Boost Price Target||Outperform||$57.00 -> $64.00||Low|
|7/10/2017||Morgan Stanley||Reiterated Rating||Equal Weight||Low|
|6/21/2017||BTIG Research||Initiated Coverage||Buy||$56.00||Low|
|5/16/2017||Goldman Sachs Group, Inc. (The)||Initiated Coverage||Neutral -> Neutral||$45.00||Low|
|8/9/2016||Deutsche Bank AG||Reiterated Rating||Buy||N/A|
|6/21/2016||Edward Jones||Upgrade||Hold -> Buy||N/A|
|6/8/2016||Credit Suisse Group||Reiterated Rating||Buy||N/A|
|4/30/2016||S&P Equity Research||Reiterated Rating||Hold||N/A|
|4/28/2016||Piper Jaffray Companies||Downgrade||Overweight -> Neutral||N/A|
|4/14/2016||First Global||Downgrade||Outperform -> Marketperform||N/A|
|3/28/2016||Leerink Swann||Boost Price Target||Market Perform||$37.00 -> $40.00||N/A|
|1/29/2016||Raymond James Financial, Inc.||Lower Price Target||Outperform||$46.00 -> $42.00||N/A|
|1/29/2016||William Blair||Downgrade||Outperform -> Market Perform||N/A|
Earnings History for Abbott Laboratories (NYSE:ABT)Earnings History by Quarter for Abbott Laboratories (NYSE ABT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|1/24/2018|| || || || || || || || |
|10/18/2017||9/30/2017||$0.65||$0.66||$6.72 billion||$6.83 billion||View||N/A|
|7/20/2017||Q2 2017||$0.60||$0.62||$6.63 billion||$6.64 billion||View||N/A|
|4/19/2017||3/31/2017||$0.43||$0.48||$6.16 billion||$6.34 billion||View||N/A|
|1/25/2017||Q416||$0.64||$0.65||$5.41 billion||$5.33 billion||View||Listen|
|10/19/2016||Q316||$0.58||$0.59||$5.29 billion||$5.30 billion||View||Listen|
|7/20/2016||Q216||$0.53||$0.55||$5.24 billion||$5.30 billion||View||Listen|
|4/20/2016||Q116||$0.39||$0.41||$4.77 billion||$4.90 billion||View||Listen|
|1/28/2016||Q415||$0.61||$0.62||$5.31 billion||$5.20 billion||View||Listen|
|10/21/2015||Q315||$0.53||$0.54||$5.16 billion||$5.15 billion||View||Listen|
|7/22/2015||Q215||$0.50||$0.52||$5.15 billion||$5.20 billion||View||Listen|
|4/22/2015||Q115||$0.42||$0.47||$4.85 billion||$4.90 billion||View||Listen|
|1/29/2015||Q414||$0.68||$0.71||$5.48 billion||$5.36 billion||View||Listen|
|10/22/2014||Q314||$0.60||$0.62||$5.62 billion||$5.10 billion||View||Listen|
|7/16/2014||Q214||$0.51||$0.54||$5.53 billion||$5.55 billion||View||Listen|
|4/16/2014||Q114||$0.36||$0.41||$5.29 billion||$5.24 billion||View||Listen|
|1/22/2014||Q413||$0.58||$0.58||$5.72 billion||$5.66 billion||View||Listen|
|10/16/2013||Q313||$0.52||$0.55||$5.46 billion||$5.37 billion||View||Listen|
|7/17/2013||Q2 2013||$0.44||$0.46||$5.53 billion||$5.45 billion||View||Listen|
|4/17/2013||Q1 2013||$0.41||$0.42||$5.42 billion||$5.38 billion||View||Listen|
|1/23/2013||Q4 2012||$1.50||$1.51||$10.58 billion||$10.80 billion||View||Listen|
Earnings Estimates for Abbott Laboratories (NYSE:ABT)
2017 EPS Consensus Estimate: $2.43
2018 EPS Consensus Estimate: $2.84
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Current Dividend Information for Abbott Laboratories (NYSE:ABT)
|Dividend Growth:||22.90% (3 Year Average)|
|Payout Ratio:||83.47% (Trailing 12 Months of Earnings) |
42.40% (Based on This Year's Estimates)
37.59% (Based on Next Year's Estimates)
|Track Record:||44 Years of Consecutive Dividend Growth|
Dividend History by Quarter for Abbott Laboratories (NYSE ABT)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Abbott Laboratories (NYSE:ABT)
Insider Ownership Percentage: 0.76%Insider Trades by Quarter for Abbott Laboratories (NYSE:ABT)
Institutional Ownership Percentage: 71.45%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/26/2017||Daniel Gesua Sive Salvadori||Insider||Sell||62,460||$52.95||$3,307,257.00|| |
|9/22/2017||Jaime Contreras||Insider||Sell||52,700||$51.97||$2,738,819.00|| |
|8/16/2017||Stephen R Fussell||Insider||Sell||196,550||$49.50||$9,729,225.00|| |
|8/1/2017||Sharon J Bracken||Insider||Sell||2,000||$49.16||$98,320.00|| |
|7/27/2017||Brian J Blaser||Insider||Sell||15,000||$50.00||$750,000.00|| |
|7/25/2017||Hubert L Allen||Insider||Sell||4,600||$50.79||$233,634.00|| |
|6/15/2017||Jared Watkin||Insider||Sell||552||$47.97||$26,479.44|| |
|6/8/2017||Stephen R Fussell||Insider||Sell||196,550||$46.00||$9,041,300.00|| |
|4/27/2017||Roger Bird||Insider||Sell||5,600||$43.82||$245,392.00|| |
|4/26/2017||Joseph J Manning||Insider||Sell||4,200||$43.95||$184,590.00|| |
|3/1/2017||Michael J. Warmuth||Insider||Sell||3,851||$45.39||$174,796.89|| |
|2/23/2017||Robert E Funck||VP||Sell||25,500||$45.50||$1,160,250.00|| |
|2/22/2017||Roger Bird||Insider||Sell||13,222||$45.02||$595,254.44|| |
|2/21/2017||Deepak S Nath||Insider||Sell||319||$44.98||$14,348.62|| |
|1/31/2017||Heather L Mason||Insider||Sell||35,700||$40.77||$1,455,489.00|| |
|12/20/2016||Brian J Blaser||Insider||Buy||15,580||$38.45||$599,051.00|| |
|12/14/2016||Robert B Ford||Insider||Buy||12,775||$39.09||$499,374.75|| |
|11/10/2016||Miles D White||Chairman||Buy||121,456||$40.45||$4,912,895.20|| |
|11/1/2016||Sally E Blount||Director||Buy||5,100||$39.24||$200,124.00|| |
|9/26/2016||Daniel Gesua Sive Salvadori||SVP||Sell||815||$41.71||$33,993.65|| |
|7/28/2016||Stephen R Fussell||Insider||Sell||41,500||$45.00||$1,867,500.00|| |
|7/26/2016||Michael J Warmuth||Insider||Sell||26,800||$43.49||$1,165,532.00|| |
|7/25/2016||Miles D White||Chairman||Buy||242,547||$43.18||$10,473,179.46|| |
|7/25/2016||Robert E Funck||VP||Sell||26,800||$43.08||$1,154,544.00|| |
|6/28/2016||Hubert L Allen||EVP||Sell||3,400||$37.14||$126,276.00|| |
|6/15/2016||Jared Watkin||SVP||Sell||552||$37.63||$20,771.76|| |
|6/1/2016||Brian B Yoor||CFO||Sell||565||$39.49||$22,311.85|| |
|4/28/2016||Deepak S Nath||SVP||Sell||53||$41.31||$2,189.43|| |
|3/31/2016||Jaime Contreras||SVP||Sell||462||$41.78||$19,302.36|| |
|2/29/2016||Brian B Yoor||CFO||Sell||865||$39.12||$33,838.80|| |
|2/29/2016||Deepak S Nath||SVP||Sell||793||$39.27||$31,141.11|| |
|2/29/2016||Robert B Ford||EVP||Sell||1,706||$39.28||$67,011.68|| |
|2/29/2016||Robert E Funck||VP||Sell||1,333||$39.30||$52,386.90|| |
|2/22/2016||Jared Watkin||SVP||Sell||554||$39.09||$21,655.86|| |
|2/16/2016||Deepak S. Nath||SVP||Sell||171||$37.13||$6,349.23|| |
|12/16/2015||Miles D. White||CEO||Sell||438,000||$46.00||$20,148,000.00|| |
|8/18/2015||Stephen R. Fussell||EVP||Sell||13,096||$50.46||$660,824.16|| |
|4/27/2015||Heather L Mason||EVP||Sell||13,500||$47.45||$640,575.00|| |
|4/27/2015||Roger Bird||SVP||Sell||28,548||$47.57||$1,358,028.36|| |
|3/26/2015||J. Scott White||SVP||Sell||12,483||$46.68||$582,706.44|| |
|3/2/2015||Jaime Contreras||SVP||Sell||9,209||$47.34||$435,954.06|| |
|2/4/2015||John M Capek||EVP||Sell||34,292||$45.66||$1,565,772.72|| |
|11/25/2014||Jaime Contreras||SVP||Sell||51,600||$44.07||$2,274,012.00|| |
|10/29/2014||Miles D White||CEO||Sell||440,800||$42.52||$18,742,816.00|| |
|3/3/2014||John Landgraf||EVP||Sell||17,293||$39.38||$680,998.34|| |
|3/3/2014||Katherine Doyle||SVP||Sell||6,639||$39.01||$258,987.39|| |
|3/3/2014||Robert Funck||VP||Sell||1,413||$38.97||$55,064.61|| |
|2/18/2014||John Landgraf||EVP||Sell||1,583||$39.10||$61,895.30|| |
|1/29/2014||Michael Warmuth||EVP||Sell||11,430||$36.21||$413,880.30|| |
|12/6/2013||Jean-Yves Pavee||SVP||Sell||5,855||$37.46||$219,328.30|| |
|11/7/2013||Stephen Fussell||EVP||Sell||10,466||$37.59||$393,416.94|| |
|10/30/2013||Jaime Contreras||SVP||Sell||25,368||$36.85||$934,810.80|| |
|6/7/2013||Heather L Mason||SVP||Sell||12,000||$37.01||$444,120.00|| |
|2/1/2013||William A Osborn||Director||Buy||10,000||$33.86||$338,600.00|| |
Headline Trends for Abbott Laboratories (NYSE:ABT)
Latest Headlines for Abbott Laboratories (NYSE:ABT)
Loading headlines, please wait.
Abbott Laboratories (ABT) Chart for Tuesday, October, 24, 2017